Paper Details

  1. Home
  2. Paper Details

Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial.

Author: , BehrensFrank, DingKevin, GottliebAlice B, GoupillePhilippe, KavanaughArthur, KorotaevaTatiana, MartinRuvie, MasmitjaJordi Gratacós, McInnesIain B, MeasePhilip J, MpofuShephard, NashPeter, PelletPascale, PricopLuminita, RitchlinChristopher

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study (EXCEED) evaluates the efficacy and safety of secukinumab versus adalimumab as first-line biological monotherapy for psoriatic arthritis.
Paper Details　
Original Abstract of the Article :
Head-to-head trials in psoriatic arthritis are helpful in guiding clinical decision making. The EXCEED study evaluated the efficacy and safety of secukinumab versus adalimumab as first-line biological monotherapy for 52 weeks in patients with active psoriatic arthritis, with a musculoskeletal primar...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/S0140-6736(20)30564-X

データ提供：米国国立医学図書館（NLM）

Comparing Secukinumab and Adalimumab for Psoriatic Arthritis

This randomized controlled trial compares the efficacy and safety of [secukinumab] versus [adalimumab] as first-line biological monotherapy for [psoriatic arthritis]. The researchers found that both treatments were effective, with [secukinumab] showing a slightly faster response rate compared to [adalimumab].

Guiding Treatment Decisions for Psoriatic Arthritis

This study provides valuable information for guiding treatment decisions for [psoriatic arthritis]. While both [secukinumab] and [adalimumab] are effective, [secukinumab] may offer a faster onset of action, potentially leading to improved outcomes for some patients.

Optimizing Treatment Strategies for Psoriatic Arthritis

These findings highlight the importance of individualized treatment approaches for [psoriatic arthritis]. By considering factors such as response rate, safety profile, and patient preferences, healthcare professionals can tailor treatment strategies to optimize outcomes for their patients.

Dr.Camel's Conclusion

This study dives into the world of [psoriatic arthritis] treatment, comparing the efficacy of [secukinumab] and [adalimumab]. Like a camel navigating the intricate paths of a desert, this research provides valuable guidance for clinicians seeking the best treatment options for their patients.

Date :
  1. Date Completed 2020-05-27
  2. Date Revised 2020-05-27
Further Info :

Pubmed ID

32386593

DOI: Digital Object Identifier

10.1016/S0140-6736(20)30564-X

Related Literature

Article Analysis
・Effective treatment of psoriatic arthritis
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.